High dose adenosine in acute myocardial infarction study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON23567

Enrollment

Registered

2008-08-04

Start date

2008-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with acute myocardial infarction treated by primary PCI

Interventions

The treatment group of 40 patients will receive intravenous adenosine 140 mug/kg per minute, during the PCI, starting before reperfusion. Non-treatment group (40 patients) will recieve care as usual

Eligibility

Inclusion criteria

Inclusion criteria: 1. Acute myocardial infarction (typical chest pain for at least 30 minutes and less then 12 hours, and > 1 mm ST-segment elevation in > 2 leads) for which primary PCI is performed.

Exclusion criteria

Exclusion criteria: 1. Haemodynamic instability 2. Severe COPD 3. Second degree atrioventriculair block 4. Persistent atrial fibrillation 5. History of myocardial infarction 6. (sub)acute stent trombosis 7. No informed consent 8. Pregnancy 9. Claustrofobia, intracerebral clips 10. Previous heart surgery or pacemaker

Design outcomes

Primary

Measure	Time frame
Area of 'no reflow' and final infarct area determined by 3 month MRI	—

Secondary

Measure	Time frame
Left Ventricle function, ST-segment resolution, enzyme release, angiographic parameters (MBG, TFC), clinical end points	—

Contacts

Public ContactM.G. Stoel

Medisch Spectrum Twente Thorax Centrum Twente

m.stoel@ziekenhuis-mst.nl+31 (0)53 4872110

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)